HEALTH NATIONAL

NAFDAC Recalls Dove Beauty Bar Soap

Written by Basirat Memudu

The National Agency for Food and Drug Administration and Control (NAFDAC) has ordered the recall of Dove Beauty Cream Bar Soap (100g) due to Butyphenyl Methylpropional (BMHCA) content.

This is made known in a statement published on its X handle said the soap is with batch number 81832M 08, produced in Germany.

Photo of the product

NAFDAC said the product violates the Cosmetic Products Regulation by containing a chemical impurity, Butyphenyl Methylpropional (BMHCA) also known as Lilial, a chemical associated with serious health risks.

The agency who explained that BMHCA has been banned in cosmetic products because it can harm the reproductive system and potentially affect the health of unborn children added that the chemical has been linked to skin sensitization, triggering allergic reactions in some users.

“As a result of the harmful effect of the BMHCA, a ban on the marketing of the product has been placed by some regulatory and public authorities, in the EU”, NAFDAC states in the statement.

According to NAFDAC, other Dove cosmetic products recalled/banned in other countries due to the presence of BMHCA are Derma Spa Goodness, Men Care, Men Care+ Sensitive Shield, Natural Touch, Nourishing Body Care Light Hydro, Pampering Body Lotion, Go Fresh, Talco con Crema, Go fresh Pera, Extra Fresh, Goodness3 Skincare Ritual, invisible dry antiperspirant spray + Go Fresh Revitalize nourishing shower gel, Caring hand wash and invisible dry.

The agency said although “these products are also not available in the NAFDAC database, Importers, distributors, retailers and consumers are advised to exercise caution and vigilance within the supply chain to avoid the importation, distribution, sale and use of the above-mentioned products”.

NAFDAC however advised members of the public in possession of the product should discontinue the sale or use and healthcare professionals and consumers are encouraged to report adverse events experienced with the use of regulated products to the nearest NAFDAC office, via pharmacovigilance@nafdac.gov.ng, E-reporting platforms available at www.nafdac.gov.ng.